0000000000560119

AUTHOR

Maria T Bourlon

showing 3 related works from this author

Survey of Fertility Preservation Options Available to Patients With Cancer Around the Globe

2020

Purpose Oncofertility focuses on providing fertility and endocrine-sparing options to patients who undergo life-preserving but gonadotoxic cancer treatment. The resources needed to meet patient demand often are fragmented along disciplinary lines. We quantify assets and gaps in oncofertility care on a global scale. Methods Survey-based questionnaires were provided to 191 members of the Oncofertility Consortium Global Partners Network, a National Institutes of Health–funded organization. Responses were analyzed to measure trends and regional subtleties about patient oncofertility experiences and to analyze barriers to care at sites that provide oncofertility services. Results Sixty-three res…

Cancer Researchmedicine.medical_specialtyReferralmedia_common.quotation_subjectBest practiceMEDLINEFertilitylcsh:RC254-282Cost EffectivenessFertilidade03 medical and health sciences0302 clinical medicineSupportive Care and Quality of LifeJournal ArticleQuality of CareMedicineFertility preservationmedia_commonOncofertilityEthicsMedicine(all)Response rate (survey)030219 obstetrics & reproductive medicinebusiness.industryHealth Services and OutcomesORIGINAL REPORTSlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensSupportive CarePolicy AnalysisWomen's cancers Radboud Institute for Health Sciences [Radboudumc 17]3. Good healthFertilityOncology030220 oncology & carcinogenesisFamily medicineScale (social sciences)Quality of Life/dk/atira/pure/researchoutput/pubmedpublicationtype/D016428business
researchProduct

Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Onc…

2023

Background: Obesity has been associated with improved response to immunotherapy in cancer patients. We investigated the role of body mass index (BMI) in patients from the ARON-1 study (NCT05287464) treated by dual immuno-oncology agents (IO+IO) or a combination of immuno-oncology drug and a tyrosine kinase inhibitors (TKI) as first-line therapy for metastatic renal cell carcinoma (mRCC). Patients and methods: Medical records of patients with documented mRCC treated by immuno-oncology combinations were reviewed at 47 institutions from 16 countries. Patients were assessed for overall survival (OS), progression-free survival (OS), and overall clinical benefit (OCB), defined as the sum of the r…

Tumor ResponseOncologySurvivalUrologyImmunocomboNCT05287464ImmunotherapyObesitymRCC
researchProduct

Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study

2023

Background: Immuno-oncology combinations have achieved survival benefits in patients with metastatic renal cell carcinoma (mRCC). Objective: The ARON-1 study (NCT05287464) was designed to globally collect real-world data on the use of immuno-combinations as first-line therapy for mRCC patients. Patients and methods: Patients aged ≥ 18 years with a cytologically and/or histologically confirmed diagnosis of mRCC treated with first-line immuno-combination therapies were retrospectively included from 47 International Institutions from 16 countries. Patients were assessed for overall survival (OS), progression-free survival (PFS), and overall clinical benefit (OCB). Results: A total of 729 patie…

Renal Cell CarcinomaImmunotherapyImmuno-oncology Combinations
researchProduct